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Abstract
Cell growth conditions and purification methods are important in determining biopharmaceutical activity. However, in
studies aimed at manufacturing virus-like particles (VLPs) for the purpose of creating a prophylactic vaccine and antigen for
human papillomavirus (HPV), the effects of the presence of a resin-bound ligand during purification have never been
investigated. In this study, we compared the structural integrity and immunogenicity of two kinds of VLPs derived from HPV
type 16 (HPV16 VLPs): one VLP was purified by heparin chromatography (hHPV16 VLP) and the other by cation-exchange
chromatography (cHPV16 VLP). The reactivity of anti-HPV16 neutralizing monoclonal antibodies (H16.V5 and H16.E70)
towards hHPV16 VLP were significantly higher than the observed cHPV16 VLP reactivities, implying that hHPV16 VLP
possesses a greater number of neutralizing epitopes and has a greater potential to elicit anti-HPV16 neutralizing antibodies.
After the application of heparin chromatography, HPV16 VLP has a higher affinity for H16.V5 and H16.E70. This result
indicates that heparin chromatography is valuable in selecting functional HPV16 VLPs. In regard to VLP immunogenicity, the
anti-HPV16 L1 IgG and neutralizing antibody levels elicited by immunizations of mice with hHPV16 VLPs were higher than
those elicited by cHPV16 VLP with and without adjuvant. Therefore, the ability of hHPV16 VLP to elicit humoral immune
responses was superior to that of cHPV16 VLP. We conclude that the specific chromatographic technique employed for the
purification of HPV16 VLPs is an important factor in determining the structural characteristics and immunogenicity of
column-purified VLPs.
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Introduction
Of all the types of human papillomavirus (HPV), type 16 is
considered to be the most significant, as it is responsible for
approximately 50% of cervical cancers [1]. HPV is an epithelio-
tropic, non-enveloped virus that has a capsid composed of L1
(major) and L2 (minor) proteins [2]. Virus-like particles (VLPs)
composed of 72 capsomeres (360 L1 proteins) are a major
component of prophylactic HPV vaccines because the VLPs are
structurally similar to naturally occurring HPV capsids and display
conformation-specific neutralization epitopes [3]. Currently, there
are two kinds of VLP-based prophylactic vaccines. One is
GardasilH (Merck), which uses a Saccharomyces cerevisiae (S. cerevisiae)
expression system, and the other is Cervarix
TM (GlaxoSmith-
Kline), which uses an insect cell expression system [4].
HPV VLPs have been used as surrogates of the native HPV
virion in studies of HPV structure, infection mechanisms and
epitope display, as the continuous production of native HPV virion
is practically impossible in vitro because the production and
assembly of native HPV virions are strictly controlled by the cell
cycle [2,5]. In addition, HPV VLPs have been used as antigens in
competitive immunoassays aimed at measuring neutralizing
antibody titers in vaccine efficacy studies [6].
Numerous viruses, including HPV, undergo conformational
changes as they interact with cell surface receptors [7,8,9], and
these conformational changes influence the selection of immuno-
dominant epitopes on the capsid surface [9]. During HPV
infection, L1 protein must first bind to heparan sulfate
proteoglycans (HSPGs) present on basement membranes (BM)
exposed by wounding [10]. The HPV capsid undergoes a
conformational change that exposes the N-terminus of the minor
capsid protein L2 when the virus interacts with HSPGs [11], and
an exposed N-terminal L2 residue is believed to interact with a
secondary receptor. The interaction between heparin and the
HPV VLP is thought to result in a VLP conformational change.
Selinka et al. have suggested that the reactivity of anti-HPV31 L1
monoclonal antibody (Mab) towards HPV31 VLPs prior to and
after heparin binding are different [7]. In addition, it has been
known that HSPGs interact with correctly folded and intact HPV
VLPs, indicating that the use of HSPG as a ligand is important in
controlling the quality of HPV VLPs.
In the manufacture of recombinant HPV VLP, the interaction
between the VLP and resin-bound ligand during purification has
the potential to affect the structure and immunogenicity of the
resulting VLP. However, the effect of the resin-bound ligand used
in manufacturing HPV VLPs has not been studied until now due
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35893to the complexity of the purification process. Previous methods
developed for purifying HPV VLPs are not only inefficient but also
inconvenient. They require several chromatography steps or
ultracentrifugation onto a sucrose cushion followed by size-
exclusion chromatography [12,13,14]. Such methods are only
useful for small-scale purification. Therefore, considerable effort
has been made to simplify and improve yields. We have developed
two single-step chromatographic methods for purifying HPV16
VLPs produced in S. cerevisiae [15]: heparin affinity chromatogra-
phy using heparin-bounded resin and cation-exchange chroma-
tography using phosphocellulose. These methods are clearly
related in that both resins are characterized by a high negative
charge density. In the former case, the charge is supplied by the
sulfate groups of the heparin, and in the latter case, the charge is
supplied by the phosphate groups of the phosphocellulose. As these
chromatographic methods are conceptually similar and require
the use of a single column type during purification, they offer a
unique opportunity to examine the effect of resin-bound ligands on
the antigenic activity of the eluted VLPs (Table 1).
In this study, we compared the structural integrity and
immunogenicity of HPV16 VLPs purified by heparin chromatog-
raphy (hHPV16 VLPs) and cation-exchange chromatography
(cHPV16 VLPs) (Table 1). Our results indicate that during the
purification of HPV VLPs, the resin-bound ligand exerts an
important influence on the structural characteristics and immu-
nogenicity of the resulting VLPs.
Results
HPV16 VLP Preparations
We prepared four types of HPV16 VLPs to investigate the effect
of the purification method on VLP conformation, and we
introduced an ammonium sulfate precipitation step to prepare
hHPV16 VLP and cHPV16 VLP (Table 1), which is useful for
removing contaminating proteins [15]. In addition, the ammoni-
um sulfate treatment increases the extent of intermolecular
disulfide bonding, which is critical for the stability of HPV VLPs
(Fig. S1) [16]. At the 26
th International Papillomavirus Confer-
ence, C.B. Buck also suggested that treatment with a low
concentration of ammonium sulfate (25 mM) in neutral pH
increases the extent of disulfide bonding [17]. In our case, we
believe that the ammonium sulfate precipitation step aids in
concentrating L1 proteins, and the high concentration allows for a
greater chance of establishing of disulfide bonds between L1
proteins. Therefore, the ammonium sulfate precipitation indirectly
facilitates disulfide bonding. In addition, this ammonium sulfate
precipitation renders the structure of the HPV16 VLP more robust
while still removing contaminating proteins. The traditional
methods for purifying the HPV VLPs produced in S. cerevisiae
use successive ultracentrifugation with a sucrose cushion, size-
exclusion chromatography and ion-exchange chromatography or
microfiltration [12,18,19,20,21]. They do not employ ammonium
sulfate precipitation or a contaminant-removal step. Therefore, we
used traditionally purified scHPV16 VLP and resin-purified
hHPV16 VLP and cHPV16 VLP to investigate the effect of the
resin-bound ligand on VLP conformation (Table 1).
Comparison of Mab reactivity towards hHPV16 VLP and
cHPV16 VLP
The HPV16 VLP binding residues for H16.V5 and H16.E70
antibodies are known to be critical for eliciting anti-HPV16
neutralizing antibodies [22]. The H16.V5 and H16.E70 antibod-
ies recognize conformational epitopes on the surface of HPV16
Table 1. Procedures used to purify the HPV16 VLPs used in this study.
Method Reference VLPs Step Purification procedure
1 15 hHPV16 VLP 1 Cell disruption
2 Ammonium sulfate precipitation (take of
precipitated protein containing HPV16 VLP)
3 Removal of precipitated contaminants (take of
soluble fraction containing HPV16 VLP)
4 Heparin chromatography
2 15 cHPV16 VLP 1 Cell disruption
2 Ammonium sulfate precipitation (take of
precipitated protein containing HPV16 VLP)
3 Removal of precipitated contaminants (take of
soluble fraction containing HPV16 VLP)
4 Cation-exchange chromatography
3 20 scHPV16 VLP 1 Cell disruption
2 Ultracentrifugation using a sucrose cushion
3 Size-exclusion chromatography
4 Cation-exchange chromatography
4 20 schHPV16 VLP
a 1 Cell disruption
2 Ultracentrifugation using a sucrose cushion
3 Size-exclusion chromatography
4 Cation-exchange chromatography
5 Heparin chromatography
All the HPV16 VLP preparations were finally dialyzed against 0.325 M NaCl in phosphate buffer pH 7.2.
aThe scHPV16 VLP was further separated by heparin chromatography.
doi:10.1371/journal.pone.0035893.t001
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339–365 located in the FG and HI loops, respectively, while
H16.E70 recognizes aa 282 in the FG loop (Fig. 1A) [24]. Thus,
H16.V5 and H16.E70 recognize different epitopes on the surface
of HPV16 VLPs, although there is some overlap in the residues
recognized by the two antibodies. The Camvir-1 antibody
recognizes a linear epitope that corresponds to residues 204–210
of HPV16 L1 [25], which are located between the EF and FG
loops (Fig. 1A). Previous reports [25,26] predict that aa 204–210
are not exposed on the surface of fully matured HPV VLP.
However, a recent study indicated that there was no significant
difference between the reactivity of Camvir-1 towards HPV16
capsomeres and HPV16 VLPs [27], indicating that the epitopes
for Camvir-1 seem to be exposed on the VLP surface.
Figure 1. Camvir-1, H16.V5 and H16.E70 reactivity towards hHPV16 VLPs and cHPV16 VLPs. The HPV16 L1 protein residues recognized
by H16.V5, H16.E70 and Camvir-1 are displayed graphically in (A). BC, CD, DE, EF, FG and HI indicate the loop structures in HPV16 L1. The numbers
refer to the amino acid residues as counted from the N-terminus, the black boxes indicate loops covering the solvent-exposed face of the capsid, and
the white box (CD) indicates an internal loop. The gray box (EF) indicates a loop partly located on the outside of the capsid. The hHPV16 VLP and
cHPV16 VLP concentrations were confirmed by SDS-PAGE prior to running ELISAs (B). The protein concentration of each VLP preparation was
determined by Bradford protein assay, and 500 to 62 ng of proteins were loaded for SDS-PAGE analysis. M indicates the molecular weight marker.
Camvir-1, H16.V5 and H16.E70 reactivity towards hHPV16 VLPs and cHPV16 VLPs was determined by direct ELISA. The ELISA results are presented in
C, D and E, respectively. The ODs of the hHPV16 VLPs after reaction with 1 mg/ml of Camvir-1, 0.25 mg/ml of H16.V5 and 0.25 mg/ml of H16.E70 were
set at 100% in C, D and E, respectively. The ELISA values are the means 6 SD of two independent assays.
doi:10.1371/journal.pone.0035893.g001
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SDS-PAGE was performed (Fig. 1B). There was no difference
between band intensities of L1 proteins in hHPV16 VLP and
cHPV16 VLP, indicating that two types of VLPs have same L1
purities and these VLPs are almost 100% pure. As shown in
Fig. 1C, Camvir-1 reacted with cHPV16 VLP more strongly than
it did with hHPV16 VLP. Therefore, it is thought that the linear
epitopes for Camvir-1 were more exposed in cHPV16 VLPs than
in hHPV16 VLP. In addition, the reactivity of H16.V5 and
H16.E70 towards hHPV16 VLPs were significantly higher than
those towards cHPV16 VLP (Fig. 1D and E).
Effect of heparin chromatography on the conformation
of HPV16 VLP
To investigate the effect of the heparin chromatography on the
conformation of HPV16 VLPs, we compared the Mab reactivity
of scHPV16 VLP before and after heparin chromatography
(Table 1). The L1 protein concentrations of the two VLP
preparations were determined by SDS-PAGE and Western
blotting prior to performing ELISAs (Fig. 2A). The proportion
of L1 protein of scHPV16 VLP was 70% of total protein while that
of schHPV16 VLP was almost 100%. L1 band intensities of
scHPV16 VLPs were corresponded with those of schHPV16 VLP
when 1.4 times more amounts of scHPV16 VLPs were loaded for
the SDS-PAGE and Western blot. For the direct ELISA,
therefore, 1.4 times more amounts of protein were coated for
scHPV16 VLP. In contrast to the results reported in Fig. 1C, the
Camvir-1 reactivity towards schHPV16 VLP was higher than the
reactivity towards scHPV16 VLP (Fig. 2B). It is assumed that
repeated chromatography resulted in the exposure of the Camvir-
1-interacting epitopes on the surface of schHPV16 VLP. At the
same time, the H16.V5 and H16.E70 reactivity towards
schHPV16 VLP were higher than those towards scHPV16 VLP
(Fig. 2C and D).
Figure 2. Camvir-1, H16.V5 and H16.E70 reactivity towards scHPV16 VLPs and schHPV16 VLPs. The amounts of L1 proteins contained in
scHPV16 VLP and schHPV16 VLP were confirmed by SDS-PAGE and Western blotting prior to performing ELISAs (A). In panel A, loading amount
indicates protein amount loaded for SDS-PAGE and Western blot. L1 amount indicates L1 protein amount contained in the loading sample. The L1
protein amount was confirmed by L1 band intensities on SDS-PAGE and Western blot. M indicates the molecular weight marker. The SDS-PAGE and
western blot are representatives of duplicate assays. The Camvir-1, H16.V5 and H16.E70 reactivity towards schHPV16 VLPs and scHPV16 VLPs were
determined by direct ELISA and are presented in B, C and D, respectively. The ODs of hHPV16 VLPs after reaction with 1 mg/ml of Camvir-1, 0.25 mg/
ml of H16.V5 and 0.25 mg/ml of H16.E70 were set at 100% in B, C and D, respectively. The ELISA values are the means 6 SD of two independent
assays.
doi:10.1371/journal.pone.0035893.g002
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To further investigate the structural integrity of the hHPV16
VLP and cHPV16 VLP, we used density gradient ultracentrifu-
gation and transmission electron microscopy (TEM) analysis, both
of which have been previously used to analyze capsid structure
[16,28,29]. The hHPV16 VLP and cHPV16 VLP were subjected
to analytical centrifugation in Optiprep density gradients (Fig. 3A).
All cHPV16 VLPs were recovered in large particles, while the
hHPV16 VLPs appeared to have been partially dissociated
(Fig. 3A). In the TEM analysis, two types of VLPs have sizes
ranging from 25 to 45 nm, and there was no significant difference
in the shape of the two VLP preparations (Fig. 3B).
We further investigated the particle size distributions of two
kinds of HPV16 VLPs using dynamic light scattering (DLS). As
shown in Fig. 4, most hHPV16 VLPs were confirmed to have sizes
ranging from 60 to 160 nm while the cHPV16 VLPs had two
different populations with sizes ranging from 40 to 100 nm and
2800 to 4200 nm, respectively. The mean hydrodynamic
diameters of the hHPV16 VLPs and cHPV16 VLPs were
confirmed to be 102 and 214 nm, respectively. In addition, it
was confirmed that both hHPV16 and cHPV16 VLPs have small
sizes of particles less than 25 nm. These results suggest that not
only VLPs but also capsomeres and L1 aggregates may be purified
by two types of purification methods.
Unlike the results of TEM, the sizes of VLPs were significantly
larger than 50 nm in DLS analysis. DLS shows how a particle
diffuses within a fluid while TEM just shows the shape and size of
each VLP particle. Therefore, it seems that HPV16 VLPs form
VLP masses or incorrectly folded L1s form aggregates when they
diffuse in solution. In summary, Fig. 4 implies that the particle
sizes of hHPV16 VLP are significantly different from those of
cHPV16 VLP in solution and cHPV16 VLPs have more L1
aggregates than hHPV16 VLPs. Increasing the hydrodynamic
diameter of HPV VLP is significantly correlated with decreasing in
vitro antigenicity [30]. Indeed, the in vitro antigenicity of the
cHPV16 VLP was confirmed to be lower than that of the hHPV16
VLP (Fig. 1). Therefore, these results re-confirm that the structural
integrity of hHPV16 VLP is significantly different from that of
cHPV16 VLP.
Humoral immune responses following immunization
with hHPV16 VLPs and cHPV16 VLPs
We compared the lipopolysaccharide (LPS) contents of
hHPV16 and cHPV16 VLP prior to immunization. The hHPV16
and cHPV16 VLP concentrations were 0.49 and 0.32 EU per
1000 ng L1 protein, respectively (Table S1). It has been clearly
demonstrated that these LPS levels do not affect humoral and
cellular immune responses in mice [31]. Additionally, it was
confirmed that the two HPV16 VLP preparations do not stimulate
immune cells in polymyxin B inhibition tests (Fig. S2). All HPV16
VLP preparations were dialyzed against 0.325 M NaCl in
phosphate buffer pH 7.2 plus 0.01% Tween 80 prior to the
immunizations.
We investigated the immunogenicity of two kinds of HPV16
VLPs through three separate protocols referred to as protocol-1, 2
and 3 (Table 2). In protocol-1, the mice were immunized four
times with 8 ng of hHPV16 VLP or cHPV16 VLP without
adjuvant. As shown in Fig. 5, the immunization of hHPV16 VLP
elicited anti-HPV16 L1 IgG and neutralizing antibody more
strongly than immunization with cHPV16 VLP. In protocol-2, the
mice were immunized three times with 1000 ng of hHPV16 VLP
or cHPV16 VLP, in combination with the adjuvant aluminum
hydroxide, to investigate prophylactic vaccine potential (Fig. 6A
and B). Immunization with hHPV16 VLP elicited anti-HPV16
neutralizing antibody more strongly than immunization with
cHPV16 VLP, but there was no significant difference in the anti-
HPV16 L1 IgG titers (Fig. 6 and Fig. S3). Additionally, the
immunogenicity of schHPV16 VLP was also confirmed to be
higher than that of scHPV16 VLP (Fig. S4). Therefore, HPV16
VLPs, which have higher affinities for H16.V5 and H16.E70 and
smaller mean hydrodynamic diameter, also demonstrated higher
general immunogenicity (Fig. 1, 2, 4, 5 and 6 and Fig. S4).
Proliferative responses of CD3
+ T lymphocytes following
immunization with hHPV16 VLPs and cHPV16 VLPs
CD3 is a well-characterized marker of T lymphocytes [32,33].
To investigate HPV16 VLP-specific proliferative responses, mice
were immunized two times with 1000 ng per mouse of hHPV16
and cHPV16 VLPs (protocol-3, Table 2). Ten days after the last
immunization, mice splenocytes were isolated and re-stimulated
with HPV16 VLP, and the number of proliferated CD3
+ cells was
scored. As shown in Fig. 7A and B, the proliferative response of
CD3
+ T cells in the hHPV16 VLP-immunization group was
significantly higher than the response observed in the cHPV16
VLP-immunization group. These results indicate that immunoge-
nicity of hHPV16 VLP in eliciting humoral and cellular immune
responses is superior to that of cHPV16 VLP.
Discussion
In this study, we compared the structural integrity and
immunogenicity of hHPV16 VLP and cHPV16 VLP. Our results
indicate that the use of heparin chromatography is more
advantageous in obtaining highly immunogenic HPV16 VLP
when compared to cation-exchange chromatography. The
epitopes of H16.V5 and H16.E70 are critical for inducing anti-
Figure 3. Analysis of the structural characteristics of hHPV16
and cHPV16 VLP. To analyze the structural integrity of the two VLP
types, the HPV16 VLPs were fractionated on Optiprep density gradients
(A). Eight fractions were collected in experiment A (0.5 ml each). The
results of TEM analysis are presented in panel B. Magnification is
41,0006(bars 50 nm).
doi:10.1371/journal.pone.0035893.g003
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affinities of hHPV16 VLP for H16.V5 and H16.E70 were
significantly higher than those of cHPV16 VLP and mean
hydrodynamic diameter of hHPV16 VLP was smaller than that
of cHPV16 VLP. These results suggest that hHPV16 VLPs may
have more neutralizing epitopes and superior antigenicity. Indeed,
the structural integrity of hHPV16 VLP was reflected by the
elicitation of anti-HPV16 neutralizing antibodies in mouse
immunization experiment (Fig. 5 and 6). Therefore, we believed
that the reactivity of H16.V5 and H16.E70 towards HPV16 VLPs
and hydrodynamic diameter of HPV16 VLP can be ideal
indicators in predicting the immunogenicity of HPV16 VLPs.
Further studies for correlation between the Mab reactivity towards
HPV16 VLP and immunogenicity of HPV16 VLP or hydrody-
namic diameter of HPV16 VLP and immunogenicity of HPV16
VLP will provide ideas for controlling quality of HPV VLP.
In this study, we separated two forms of hHPV16 VLP by
analytical ultracentrifugation: a fully assembled and a dissociated
form (Fig. 3A). A TEM analysis indicated that the hHPV16 VLPs
appear to be fully assembled (Fig. 3B), but the lack of a monomer
band in non-reducing Western blots of hHPV16 VLPs points to
the existence of a dissociated form (data not shown). Moreover, it
was confirmed most hHPV16 VLPs have sizes between 60 and
160 nm, indicating that those are assembled forms or L1
aggregates (Fig. 4A). Therefore, we assume that the hHPV16
VLP is partially dissociated by hydrostatic pressure during
ultracentrifugation (Fig. 3A).
Previously, we confirmed that the final yields of L1 protein
resulting from heparin and cation-exchange chromatography are
similar [15]. In this study, however, we found that the structure
and immunogenicity of the two kinds of HPV16 VLPs were
different. Moreover, cHPV16 VLPs were confirmed to contain
more L1 aggregates while hHPV16 VLP did not (Fig. 4). These
results indicate that the heparin-bound resin more efficiently
selects for the correctly assembled HPV16 VLP than phosphate-
bound cation exchange resin.
The shielding of key epitopes within the three-dimensional
structure of the native envelope trimer of human immunodefi-
ciency virus (HIV) is a major problem in neutralizing vaccine
development because the conformational masking offers the virus
an opportunity to evade host defenses [36,37]. This conforma-
tional camouflage has also been observed in the case of human
parvovirus (HP) B19. HP B19 exposes neutralization epitopes and
can be neutralized by neutralizing antibody only after it binds to its
receptor on the cell surface [38]. In recent years, the VLP has been
used as a platform to display heterogeneous epitopes [39,40].
Therefore, developing strategies to control epitope display is a high
priority in the vaccine field. Our results indicate that the choice of
resin-bound ligand during downstream processing affects the
displays of epitopes on the surface of virus capsids. We anticipate
Figure 4. Particle size distributions of hHPV16 VLP and cHPV16 VLP. The HPV16 VLP populations along with their associated hydrodynamic
diameters were analyzed by DLS as described in the Materials and Methods section. Each HPV16 VLP was prepared in 25 mM MOPS containing
75 mM NaCl pH 7.0 and adjusted to 40 mg/ml. Panel A and B are representatives of duplicate measurements of the hHPV16 VLP and cHPV16 VLP
populations, respectively.
doi:10.1371/journal.pone.0035893.g004
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provide additional information to aid in efforts to control surface
epitope display.
Previously, it has been suggested that the upstream and
downstream processing of virus-like particles during production
may affect to their structure and immunogenicity [41]. However,
there have been considerable limits on the methods used to
determine the best chromatography system to use during
purification [42,43] due to a dearth of information how the
choice of resin-bound ligand affects the function of the final
recovered VLP product. Moreover, until now, there was no study
examining how structure and immunogenicity can be directly
affected by the manufacturing process. In summary, the results of
our study indicate that differences in manufacturing processes can
result in functional differences in purified HPV VLP. The resin-
bound ligand used in purifying HPV VLPs is an important
determinant of the quality and characteristics of the resulting HPV
VLP preparation.
Materials and Methods
Ethics
Five- to six-week-old female BALB/c mice were purchased from
Orient Bio (Orient Bio, South Korea) and acclimatized for 1 week
prior to immunization. All animal experiments were performed in
accordance with the National Research Council’s Guidelines for
the Care and Use of Laboratory Animals and with the Chung-Ang
University Guidelines for Animal Experiments. In addition, all
experiments were approved by the University Committee for
animal experiments (approval no. 10-1017).
Expression and purification of HPV VLPs
HPV16 VLPs were expressed in HPV16 VLP-producing S.
cerevisiae [44]. The detailed purification procedure used for each
HPV16 VLP preparation is presented in Table 1. The hHPV16
and cHPV16 VLPs were purified as previously described [15], and
the HPV16 VLP was purified by size-exclusion and cation-
exchange chromatography (scHPV16 VLP) as previously de-
scribed [12,20]. To compare the conformations of the HPV16
VLPs before and after heparin chromatography, pre-heparin
chromatography scHPV16 VLP was used. This HPV16 VLP was
further separated by heparin chromatography and designated
schHPV16 VLP (Table 1). All HPV16 VLP preparations were
finally dialyzed against 0.325 M NaCl in phosphate buffer pH 7.2
plus 0.01% Tween 80 prior to performing experiments.
Determination of protein concentration
Protein concentration of each VLP preparation was determined
with a Bio-Rad Bradford protein assay kit (Bio-Rad Laboratories,
USA) with bovine serum albumin (BSA; Pierce, USA) as standard.
The purities of L1 proteins were further determined by SDS-
PAGE and Western blot analysis described below.
Direct ELISA using Mabs against HPV16 L1
ELISAs were performed as previously described [27] to
investigate the reactivity of Mabs towards HPV16 VLPs.
H16.V5 and H16.E70 Mabs were kindly provided by Dr. N. D.
Christensen (Pennsylvania State University, College of Medicine
USA). Camvir-1 was purchased from Chemicon (Chemicon,
USA). A 96-well ELISA plate (Greiner Bio1one, Germany) was
coated overnight at 4uC with 400 ng of HPV16 VLP per well. The
plate was blocked with 5% skim milk in PBS plus 0.05% Tween 20
(PBST), and then each of the three Mabs was serially diluted and
incubated for 1 h at 37uC. The bound Mabs were detected using
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(diluted 1:5000, Bethyl Laboratories, USA). The samples were
colorimetrically developed with o-phenylenediamine (Sigma,
USA) and measured at an absorbance of 492 nm.
SDS-PAGE and Western blot analysis
SDS–PAGE was performed using the Laemmli method [45].
Western blot analysis was performed as previously described [20].
The band corresponding to L1 protein was detected using rabbit
anti-HPV16 L1 polyclonal antibody together with anti-rabbit IgG
antibody (Pierece, USA). The rabbit anti-HPV16 L1 Pab was
kindly provided by Dr. J.T. Schiller (NIH, Bethesda, USA). All
samples were fractionated using 12% polyacrylamide gels.
Optiprep density gradients
Optiprep density gradient analysis was performed as previously
described [46]. Beckman polyallomer tubes (Beckman Coulter,
Fullerton, CA) were successively packed from the bottom of the
tube with 39, 33 and 27% iodixanol (Sigma, USA) in phosphate-
buffered saline (PBS) containing 0.8 M NaCl and purified HPV16
Figure 5. Immunization Protocol-1 Anti-HPV16 L1 IgG titer and neutralization activity resulting. Mice were immunized according to
immunization protocol-1 (Table 2). The mice were immunized four times with 100 ml of PBS, 8 ng of hHPV16 VLP or 8 ng of cHPV16 VLP at two-week
intervals, in the absence of adjuvant. Ten days after the 3
rd and 4
th immunization, the mice sera were obtained and analyzed. Panels A and B present
the anti-HPV16 L1 IgG titer and neutralization activity after the 3
rd immunization, respectively. Panels C and D present the anti-HPV16 L1 IgG titer and
neutralization activity after the 4
th immunization, respectively. The horizontal bars are median values of the IgG titer and neutralization activity (PBS,
n=6; hHPV16 VLP, n=15; cHPV16 VLP, n=15).
doi:10.1371/journal.pone.0035893.g005
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Next, 500-ul fractions were collected in siliconized microcentrifuge
tubes (Sigma, USA) by puncturing the bottom of the tube, and
HPV16 L1 proteins were detected using SDS-PAGE and western
blotting as described above.
Transmission electron microscopy (TEM)
For TEM analysis, purified hHPV16 VLP and cHPV16 VLP
were prepared and analyzed as previously described [44].
Dynamic light scattering (DLS)
The size distribution of each HPV16 VLP was analyzed using a
DLS-700 system (Otsuka Electronics, Japan) at 23uC. Each
HPV16 VLP was prepared in 25 mM MOPS containing
75 mM NaCl pH 7.0 (final conc. of L1s were adjusted to
40 mg/ml). The preparations were measured using duplicate
assays, and the representative result of each VLP preparation was
presented.
Mice Immunization
Three kinds of immunization protocols were used to investi-
gating the immunogenicity of the HPV VLPs. The protocols are
briefly summarized in Table 2. In immunization protocol-1, six-
week-old female mice were divided into three groups, each
consisting of 6 or 8 mice. A control group was given PBS, and the
hHPV16- and cHPV16 VLP-immunization groups received
subcutaneously injections of 8 ng of hHPV16 VLP or cHPV16
VLP without adjuvant. The three groups were immunized four
times at two-week intervals (Table 2). In immunization protocol-2,
a control group was given PBS in combination with aluminum
hydroxide (200 mg per dose) [47]. The hHPV16 VLP- and
cHPV16 VLP-immunization groups each received subcutaneously
injections of 1000 ng of hHPV16 VLPs or cHPV16 VLP, in
combination with aluminum hydroxide (200 mg per dose). The
three groups were immunized three times at two-week intervals
(Table 2). In protocol-3, to investigate the lymphoproliferative
responses elicited by immunizations with the two kinds of HPV16
VLPs, the mice were immunized two times at two-week intervals
with 1000 ng of hHPV16 VLPs or cHPV16 VLP, in combination
with aluminum hydroxide (200 mg per dose, Table 2). The
immunization doses were based on a previous report [27]. Ten
days after the last boost injection, splenocytes were obtained from
each group for flow cytometry analysis. Sera were obtained by
centrifugation of whole blood, and stored at 270uC until analysis.
Carboxyfluorescein succinimidyl ester-based splenocyte
proliferation assay
Splenocytes from the PBS-, hHPV16 VLP- and cHPV16 VLP-
immunized mice were labeled with carboxyfluorescein succinimi-
dyl ester (CFSE) using a CellTrace
TM CFSE cell proliferation kit
(Invitrogen, USA). The CFSE-labeled splenocytes were cultured in
96-well flat-bottom cell culture plates (1.2610
6 cells/well) for 5 day
at 37uC with 10 mg/ml of HPV16 VLP (hHPV16 VLP and
cHPV16 VLP mixed in a 1:1 ratio). The cells were harvested,
washed with staining buffer (1% FBS in PBS) and stained with
anti-mouse CD3 peridinin chlorophyll protein-eFluorH 710
(PerCP-eFluorH) antibody (eBioscience, USA). The cells were
washed twice with the staining buffer, and the stained cells were
examining with a FACSAria flow cytometer (BD Bioscience,
USA). Thirty thousand events were acquired with the live
lymphocyte gates during the scoring of proliferated CD3
+ CFSE
low
cells.
Titration of anti-HPV16 L1 IgG
The titers of anti-HPV16 L1 IgG in the mouse sera were
determined by indirect ELISA as previously described [48].
Briefly, 96-well ELISA plates were coated and incubated overnight
with 100 ng of cHPV16 VLP per well at 4uC and blocked with 2%
BSA in PBST. Serial three-fold dilutions of serum were added to
the wells and incubated for 1 h at 37uC. Next, HRP-conjugated
Figure 6. Immunization Protocol-2 Anti-HPV16 L1 IgG and neutralization antibody titers. The anti-HPV16 L1 IgG and anti-HPV16
neutralizing antibody titers of the PBS-, hHPV16 VLP- and cHPV16 VLP-immunization groups are presented in panels A and B, respectively. For the
immunizations, the mice were subcutaneously injected three times with 100 ml of PBS, 1000 ng of hHPV16 VLP or 1000 ng of cHPV16 VLP at two-
week intervals (protocol-2 in Table 2). The anti-HPV16 L1 IgG and anti-HPV16 neutralizing antibody titers were determined by ELISA and SEAP-based
neutralization assays, respectively. The data values of seven individual mice (n=7) are represented with dots. The horizontal bars indicate the median
titers of the anti-HPV16 L1 IgG and neutralization antibodies.
doi:10.1371/journal.pone.0035893.g006
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1 h at 37uC. The color reaction was developed as described in the
direct ELISA section above. End-point titers were established at
an OD of 2 times the OD of the control serum [12].
Neutralization assay
To investigate the neutralizing ability of anti-HPV16 L1 mouse
sera, a pseudovirus (PsV)-based neutralization assay was per-
formed as previously described [49]. The plasmids p16sheLL
(containing both HPV16 L1 and L2 gene) and pYSEAP (reporter
plasmid) were kindly provided by Dr. J.T. Schiller (NIH, Bethesda,
USA). For the neutralization assay, 293TT cells were seeded in 96-
well tissue culture plates at a density of 3610
4 cells/well and
incubated for 4 h at 37uC. Optiprep density gradient-purified PsV
stock was diluted 400-fold and incubated with dilutions of the sera
at 4uC for 1 h. Next, the PsV-serum mixtures were added to the
seeded cells and further incubated for 72 h at 37uC. The secreted
alkaline phosphate (SEAP) activity of the culture supernatants was
measured by a colorimetric SEAP assay. The neutralization
activities of the mice sera obtained from immunization protocol-1
were determined as described previously with slight modification
[27]. The equation is as follows: neutralization (%)=(value for
PsV alone2value for PsV mice serum)/(value for PsV alone2-
value for blank)6100. The neutralization antibody titers of the
mice sera obtained from immunization protocol-2 were deter-
mined as the reciprocal of the highest dilution that caused at least
a 50% reduction in SEAP activity when compared to controls
treated with PsV alone.
Figure 7. In vitro CD3
+ cell proliferation measured using CFSE labeling. To measure HPV16 VLP-specific CD3
+ cell proliferation, mice were
immunized two times with 1000 ng of hHPV16 VLP or cHPV16 VLP at a two-week interval (protocol-3 in Table 2). The PBS-immunization group
received 100 ml of PBS using same protocol described above. Ten days after the last immunization, mice spleens were isolated and labeled with CFSE.
The CFSE-labeled spleen cells were re-stimulated with 10 mg/ml of HPV16 VLP (hHPV16 VLP and cHPV16 VLP in a 1:1 ratio) and cultured for 5 days.
CD3
+ cells were detected using anti-mouse CD3 PerCP-eFluorH 710 antibodies. Panel A is representative the flow cytometry results of three individual
mice demonstrate the proliferation of CD3
+ total live lymphocyte cells. To score proliferated CD3
+ cells, total live lymphocytes were gated from
forward and side scatter, and the upper-left segment of each graph was counted using FITC and PerCP eFluor scatter. Panels B presents the mean 6
SEM (n=3).
doi:10.1371/journal.pone.0035893.g007
Conformation of HPV16 VLP on Immunogenicity
PLoS ONE | www.plosone.org 10 April 2012 | Volume 7 | Issue 4 | e35893Statistical analysis
The statistical significance of differences between groups was
determined using two-tailed Student’s t-tests. P,0.05 indicated a
statistically significant difference.
Supporting Information
Figure S1 Effect of ammonium sulfate precipitation on
the extension of intermolecular disulfide bonding of
HPV16 VLP. To compare the degrees of intermolecular disulfide
bonding between HPV16 VLPs before and after ammonium
sulfate precipitation, non-reducing Western blotting was per-
formed as described at the website of National Cancer Institute
(NCI) (http://home.ccr.cancer.gov/Lco/ImprovedMaturation.
htm). To detect HPV16 L1 protein, rabbit anti-HPV16 L1
polyclonal antibody and HRP-conjugated goat anti-rabbit IgG
was used.
(TIF)
Figure S2 Measurements of endotoxin levels contained
in hHPV16 VLP and cHPV16 VLP. To measure the endotoxin
levels, RAW264.7 (2610
4 cells / well) cells were seeded in a 96-
well cell culture plate 24 hours prior to stimulations. To block
Toll-like receptor 4 on RAW264.7 cells, the cells were treated with
50 mg/ml of polymyxin B (Sigma, USA) for 30 min at 37uC prior
to LPS and HPV VLPs treatments. The cells were treated with
LPS, hHPV16 VLP and cHPV16 VLP at concentrations of
10 ng/ml, 10 mg/ml and 10 mg/ml, respectively. Four hours after
the treatments, the levels of TNF-a in the culture supernatants was
measured using an ELISA kit according to manufacturer’s
instructions (BD Bioscience, USA). Values are presented as the
means 6 SD of duplicate assays.
(TIF)
Figure S3 Neutralization assay results. The mice were
immunized three times with 1000 ng of hHPV16 VLP or cHPV16
VLP, in combination with aluminum hydroxide (protocol-2,
Table 2). The mice sera were serially diluted and incubated with
Optiprep density gradient-purified HPV16 PsVs for 1 h at 4uC.
The PsV and mice sera mixtures were added to pre-plated 293TT
cells and cultured for 72 h at 37uC. The secreted SEAP of each
well was developed using a 4-nitrophenly phosphate disodium salt
hexahydrate (Sigma, USA). B and P of the figure captions indicate
the ells cultured with media only (blank) and PsV only,
respectively.
(TIF)
Figure S4 Anti-HPV16 L1 IgG titers and neutralization
activities of mice sera following immunizations with
schHPV16 and scHPV16 VLP. Mice were immunized
subcutaneously three times with 8 ng of schHPV16 VLP or
scHPV16 VLP without adjuvant. Ten days after the last
immunization, the sera were obtained and analyzed as described
in the Materials and Methods to determine the anti-HPV16 L1
IgG titers and neutralization activities. The horizontal bars are the
median values (PBS, n=6; schHPV16 VLP, n=8; scHPV16 VLP,
n=8).
(TIF)
Table S1 Determinations of LPS levels in Mock and
HPV16 VLPs. Mock samples were prepared form the cell lysate
of parent cell of HPV16 L1-producing S. cerevisiae. The
concentrations of hHPV16 VLP and cHPV16 VLP were
determined by SDS-PAGE and Western blotting prior to the
assay. The LPS level of each sample was determined using the
limulus amoebocyte lysate (LAL) based colorimetric system
(ToxinSensor
TM, GenScript, USA) according to the manufacture’s
instruction.
(DOCX)
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